Unexpectedly potent protein droplets – Berlin researchers discover new pathomechanism of hereditary diseases

Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease...

More

NOXXON PROVIDES UPDATE ON CLINICAL TRIAL RECRUITMENT AND CORPORATE OPERATIONS DURING COVID-19 PANDEMIC

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided a corporate update on its measures in response to the potential impact of...

More

Launching the COVID-19 manufacturing fund

Opening a fund to help to ensure vital parts for COVID-19 related projects are manufactured.

More

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program,...

More

Progress towards an MVP to globally benchmark AI symptom assessments

 

“In the beginning, no one could really imagine how such complex systems like ‘AI symptom checkers’ could be benchmarked, but now this topic group is showing to be actually cracking this nut.” Developing an internationally recognized standardized...

More

Digital collaboration on rare diseases

Twenty university hospitals and other partner institutions have joined forces across Germany under the CORD-MI (Collaboration on Rare Diseases) project to improve patient care and research in the field of rare diseases. CORD-MI has been funded by the...

More

Recognise and control new variants of the deadly Ebola virus more quickly

The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time. Whilst the risks associated with the novel coronavirus are still...

More

Fine-tuning gene scissors: Computer model for adjusting CRISPR-Cas9 enables more precise cuts in the genome

The CRISPR-Cas9 gene-editing tool makes it possible to modify the genetic material of organisms. But CRISPR technology is not perfect. Frequently, these molecular “scissors” also make incisions in genetic regions that have a similar appearance to the...

More

Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic

ID: SC1-PHE-CORONAVIRUS-2020

More

STARTUP PITCH & PARTNER APPLICATION

 

We welcome applications from young European start-up companies looking to expand their profile, advance their business ideas and build relationships with life-science investors and supporters of innovation.

European life-science spin-offs and...

More
Show more items